April 16, 2018  |  BusinessWire


Coalition’s first priority is to serve as the official sponsor of GBM AGILE, an adaptive platform trial for patients with glioblastoma – the most common and deadliest form of brain cancer

 

LEXINGTON, Mass. (April 16, 2018) – Global Coalition for Adaptive Research (GCAR), a 501(c)(3) nonprofit charitable organization, comprised of some of the world’s foremost clinical, translational and basic science investigators working collectively to help speed the discovery and development of cures for rare and deadly diseases, announced its official launch today. As its first priority, GCAR will serve as the official sponsor of GBM AGILE, an adaptive platform trial for patients with glioblastoma (GBM) – the most common and deadliest of malignant primary brain tumors.

“We believe our dedication to the advancement of science through innovative trial design will ultimately result in better treatments and drive rapid progress in order to make a real difference in patients’ lives,” said Dr. Brian M. Alexander, GCAR president and chief executive officer. “Our first effort seeks to improve treatment options for patients with glioblastoma – of which there is no known prevention or early detection methods, few available treatment options, and no cure.”

Initial Goals
GCAR will first aim to operationalize GBM AGILE, a platform trial to identify new and effective therapies for glioblastoma. In addition, it will work to create a repository of clinical, safety and biomarker data from GBM patients to serve as an important tool for further understanding of this deadly disease. Finally, GCAR, using GBM AGILE as a model for the efficient evaluation and development of therapies and biomarkers, will build additional platform trial collaborations to support the evaluation of drugs for rare and deadly diseases.

GBM AGILE Overview
GBM AGILE is an international, seamless Phase II (efficacy and safety)/Phase III (confirmatory) trial designed to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. The goal is to identify effective therapies and the most promising biomarker-defined populations for those therapies in patients with glioblastoma. GBM AGILE is a flexible and adaptable approach that allows researchers to study the effects of multiple treatment options simultaneously. Furthermore, new treatments and biomarkers can be added after the trial has started, creating a learning system in perpetuity.

GBM AGILE is changing the IDEA of clinical trials:

  • Innovative – Next-generation trial that will lower cost of development and speed progress.
  • Dynamic – Perpetual learning system to quickly add potentially promising new drugs and drop those that appear to be ineffective.
  • Efficient – Design and trial structure that will require fewer patients and a shorter time frame to get important answers about a drug’s effectiveness.
  • Accessible – Global effort open to a broad patient population newly diagnosed and recurrent GBM patients.

GCAR Leadership
The Global Coalition for Adaptive Research will be headquartered in Lexington, Mass. and led by an accomplished team of individuals.

Executive Team:

  • Brian M. Alexander, M.D., M.P.H., President and Chief Executive Officer; Associate Professor, Radiation Oncology, Harvard Medical School; Disease Center Leader for Radiation Oncology, Center for Neuro-Oncology, Dana-Farber/Brigham and Women’s Cancer Center; Deputy Director for Regulatory Science, Harvard/MIT Center for Regulatory Science
  • Tim Cloughesy, M.D., Chief Medical Officer and Board Member; Director, Neuro-Oncology Program, Professor, Neurology, David Geffen School of Medicine University of California, Los Angeles
  • Webster Cavenee, Ph.D., Chief Scientific Officer; Director, Ludwig Institute for Cancer Research; Distinguished Professor, University of California, San Diego
  • W.K. Alfred Yung, M.D., Executive Vice President of International Collaborations; Chairman, Department of Neuro-Oncology, Margaret and Ben Love Chair in Clinical Cancer Care, University of Texas, MD Anderson Cancer Center

Board of Directors:

  • Faramarz Yousefzadeh, J.D., LL.M., Chairman of the Board; Chairman, Windmill Capital
  • Tim Cloughesy, M.D., Board Member and Chief Medical Officer; Director, Neuro-Oncology Program, Professor, Neurology, David Geffen School of Medicine University of California, Los Angeles
  • Sujuan Ba, Ph.D., Board Member; President and Chief Operating Officer, National Foundation for Cancer Research
  • John Frishkopf, M.M.S., Board Member; Founder and President, Drumlin Field Ventures; Director, Trinitas Capital Management

Strategic Partners
The Global Coalition for Adaptive Research appreciates the generosity, dedication and collaboration of its strategic partners who play an important role in furthering GCAR’s mission of speeding the discovery and development of cures for patients with rare and deadly diseases. GCAR’s initial strategic partners include the following organizations:

  • Berry Consultants
  • Novella Clinical
  • National Foundation for Cancer Research
  • Cure Brain Cancer Foundation
  • Eliminate Cancer Initiative
  • Minderoo Foundation
  • Wilson Sonsini Goodrich & Rosati

To learn more about GCAR, visit our website: www.gcaresearch.org. Additionally, “like” us on Facebook at https://www.facebook.com/Global-Coalition-for-Adaptive-Research-140599016703455/, follow us on Twitter and add us on Instagram at @GCAResearch.

 

About Global Coalition for Adaptive Research
The Global Coalition for Adaptive Research (GCAR) is a 501(c)(3) nonprofit charitable organization, comprised of some of the world’s foremost physicians, clinical researchers and investigators united in expediting the discovery and development of cures for patients with rare and deadly diseases. As its first priority, GCAR is the official sponsor of GBM AGILE, an adaptive platform trial for patients with glioblastoma (GBM) – the most common and deadliest of malignant primary brain tumors. To learn more, visit: www.gcaresearch.org

 

CONTACT:
Coast Public Relations for GCAR
Andrew Meehan, 949-285-0759
andrew@coastprgroup.com